Tylenol maker pushes back as Trump administration moves to link acetaminophen to autism

The Trump administration is preparing to announce findings that prenatal exposure to acetaminophen, the active ingredient in Tylenol, may be associated with an increased risk of autism in children, a claim the White House has cast as part of its broader push to address rising autism rates. Health and Human Services Secretary Robert F. Kennedy Jr. has made tackling the condition a priority, noting that current estimates place autism in about one in 31 children, up from roughly one in 150 in 2000.

Kenvue, the company that makes Tylenol, pushed back decisively on the administration’s planned claim, calling it dangerous and insisting there is no credible evidence linking acetaminophen to autism. In a statement, a company spokeswoman said, "We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers." She added: "Acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy. Without it, women face dangerous choices: Suffer through conditions like fever that are potentially harmful to both mom and baby or use riskier alternatives. The facts are that over a decade of rigorous research, endorsed by leading medical professionals and global health regulators, confirms there is no credible evidence linking acetaminophen to autism. We stand with the many public health and medical professionals who have reviewed this science and agree. We will continue to explore all options to protect the health interests of the American women and children."

The administration’s move comes amid ongoing debate over whether acetaminophen, widely used by pregnant women to manage fever and pain, could influence fetal brain development. The drug is considered among the safest, doctor-approved options for use during pregnancy, and about 60 percent of pregnant women reportedly take acetaminophen during pregnancy to treat fevers or pain that could harm both mother and baby. In the United Kingdom, the drug is known as paracetamol and appears in Tylenol and other over-the-counter products, including DayQuil, NyQuil, and Excedrin PM.

Several major medical groups have cautioned that, while some studies have reported associations between prenatal acetaminophen use and later neurodevelopmental outcomes, there is no consistent or robust evidence of causation. The American College of Obstetricians and Gynecologists has long endorsed the drug’s safety for use in pregnancy when directed by a clinician, though they advise discussing symptoms and dosage with a health care professional. Across the medical literature, researchers emphasize that many studies show no effect or only weak associations, and confounding factors—such as maternal illness, fever, and other environmental influences—likely play a role in observed outcomes.

This year has already seen diametrically opposed research signals. A major paper involving more than 100,000 people from Mount Sinai and Harvard’s School of Public Health, published in Environmental Health, reported what the authors called the strongest evidence to date of a link between prenatal acetaminophen use and an increased risk of ADHD in children, while noting the study design is observational and cannot establish causation. The researchers urged caution and recommended using the lowest effective dose for the shortest possible duration if treatment is necessary during pregnancy. They also highlighted that the literature remains inconsistent, with other studies finding no association.

Independent experts reviewed the Mount Sinai-Harvard findings and stressed that association does not equal causation. Dr. Monique Botha, a developmental psychologist at Durham University in the United Kingdom, said in a Science Media Center briefing: "There is no robust evidence or convincing studies to suggest there is any causal relationship, and any conclusions being drawn to the contrary are often motivated, under-evidenced, and unsupported by the most robust methods to answering this question. I am exceptionally confident in saying that no relationship exists." Dr. Hannah Kirk, a developmental psychologist at Monash University, echoed the sentiment, adding: "No study has shown that paracetamol [acetaminophen] causes autism. Some studies have reported an association between paracetamol [acetaminophen] use and autism, while others have not. Importantly, association does not mean causation."

FDA and independent researchers continue to monitor data on prenatal acetaminophen exposure, while clinicians emphasize that pain management in pregnancy remains essential and that fever itself can pose risks to both mother and fetus if left untreated. Pregnant women are generally advised to avoid certain nonsteroidal anti-inflammatory drugs, such as ibuprofen, due to concerns about miscarriages and low birth weight, and to consult a clinician about safe options.

The political dimension of the issue intensified after the president’s remarks at a memorial service and subsequent events. President Donald Trump, during an aside at Charlie Kirk’s memorial service, teased that an important autism-related announcement would be forthcoming, stating, "I think we found an answer to autism" and that the administration would not let it happen anymore. He had earlier hinted at a major announcement at an American Cornerstone Institute event, signaling that the issue would be prioritized publicly by his administration. Critics, including health policy experts, have argued that there is little robust evidence to back a causal link between acetaminophen and autism and warned that policy changes could create fear and unintended consequences for pregnant women seeking safe and effective fever and pain relief.

Beyond the science and politics, the debate underscores a broader challenge in communicating risk to the public. While some families search for explanations for rising autism rates, medical researchers caution against drawing definitive conclusions from observational data alone. The current landscape includes a mix of studies with varying methodologies and results, and major medical organizations reiterate the importance of individualized medical guidance during pregnancy.

As policymakers prepare to present their findings, health officials, physicians, and expectant mothers will weigh the risks and benefits of acetaminophen use in pregnancy. The administration’s proposal, if advanced, would need thorough vetting by federal scientific advisory bodies and careful consideration of potential public health consequences. While the exact timing and scope of the announcement remain uncertain, the episode highlights how health policy and science can collide in the public sphere, with consequences felt in stock markets, medical practice, and family decisions alike.